J. Hyung

发表

Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma

J. Huh, C. Suh, J. Ryu, 2019, Blood research.

Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma

Sang‐wook Lee, J. Huh, C. Suh, 2019, Annals of Hematology.

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

Jae Hoon Lee, Song-Cheol Kim, H. Chang, 2020, British Journal of Cancer.

Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX

B. Ryoo, H. Lee, J. Jeong, 2022, ESMO open.

Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer

C. Sung, Jihun Kim, S. Kim, 2022, Cancer research and treatment.

Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients

H. Chang, Myung-Hwan Kim, D. Park, 2017, Cancer Chemotherapy and Pharmacology.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2022, Journal of Cancer Research and Clinical Oncology.

Prognostic factors in patients (pts) with advanced biliary tract cancer (BTC) treated with first-line gemcitabine plus cisplatin (GEMCIS): Retrospective analysis of 740 pts.

H. Chang, Myung-Hwan Kim, D. Park, 2017 .

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

H. Chang, B. Ryoo, B. Kim, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients

H. Chang, B. Ryoo, S. Park, 2017, British Journal of Cancer.

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

Song-Cheol Kim, H. Chang, Hyung-seung Jin, 2020, British Journal of Cancer.

Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis

C. Yoo, S. Chun, T.W. Kim, 2023, ESMO open.

Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial.

G. Abou-Alfa, J. Cheon, B. Ryoo, 2023, JAMA oncology.

Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection.

Song-Cheol Kim, D. Park, T. Song, 2023, Cancer research and treatment : official journal of Korean Cancer Association.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2022, Journal of Cancer Research and Clinical Oncology.

21‐gene expression assay and clinical outcomes of premenopausal patients with hormone receptor‐positive breast cancer

Sung-Bae Kim, G. Gong, K. Jung, 2023, International journal of cancer.

Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma

S. Chan, C. Yoo, J. Hyung, 2023, Liver Cancer.

Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair.

Hyung-Don Kim, J. Hyung, M.H. Ryu, 2024, Gastric Cancer.

Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression.

Hyung-Don Kim, J. Hyung, M. Moon, 2024, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association.